Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, specializing in the discovery and development of antibody-based therapeutics primarily for cancer and other serious diseases... Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, specializing in the discovery and development of antibody-based therapeutics primarily for cancer and other serious diseases. Founded in 1998, it focuses on innovative human antibody technologies to create differentiated products that address unmet medical needs in oncology and beyond. Key marketed products include EPKINLY and TEPKINLY for relapsed or refractory diffuse large B-cell lymphoma, follicular lymphoma, and other B-cell malignancies; and Tivdak for recurrent or metastatic cervical cancer post-chemotherapy. The company also generates significant royalties from partnerships, notably DARZALEX for multiple myeloma, marketed by Johnson & Johnson. Genmab A/S maintains a robust pipeline with investigational candidates like epcoritamamab, rinatabart sesutecan, and others targeting solid tumors, blood cancers, and rare diseases through collaborations with AbbVie, Pfizer, and Novartis. Recently, it expanded via an $8 billion acquisition of Merus N.V., bolstering its late-stage oncology assets including petosemtamab. With over 2,600 employees, Genmab A/S plays a pivotal role in advancing precision oncology, driving revenue growth through royalties, product sales, and pipeline maturation.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

No Waste Management data disclosed by Genmab

We reviewed Genmab's website and available disclosure materials for the 2023 reporting period and did not identify any reported Waste Management data.

If you would like us to review newly published materials or reassess the most recent disclosures, you can submit a data update request.

Would you like us to review Genmab's data?

Start your 30-day free trial to request a data review for Genmab.

Start Free Trial

Legal Center Contact Us